SCHEMBL2820547

SCHEMBL2820547

CCc1nc2cc(Cl)c(F)cc2c(OC(=O)OC(C)C)c1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ACACB O00763 1/20 0.32
PTGS2 P35354 2/20 0.32
KDM4E B2RXH2 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
GAA P10253 1/20 0.30
TSPO P30536 1/20 0.30
PTGDR2 Q9Y5Y4 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820005 0.91 ALDH1A1 (0.34) ALDH1A1LMNAHPGDSMN1; SMN2TDP1
SCHEMBL2823400 0.85 GAA (0.33) ALDH1A1LMNATDP1PTGS2KDM4E
SCHEMBL2819903 0.80 USP2 (0.36) HPGDSMN1; SMN2ACACBKDM4EMEN1
SCHEMBL2823122 0.80 ALDH1A1 (0.38) ALDH1A1LMNAHPGDKDM4EL3MBTL1
SCHEMBL2819546 0.78 KDM4E (0.31) ALDH1A1KDM4EL3MBTL1MEN1KMT2A
SCHEMBL2823560 0.78 KMT2A (0.35) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL2819552 0.76 KDM4E (0.32) ALDH1A1TDP1KDM4EL3MBTL1MEN1
SCHEMBL2819564 0.76 PTGS2 (0.37) ALDH1A1LMNAHPGDSMN1; SMN2ACACB
SCHEMBL2823361 0.75 GAA (0.35) ALDH1A1LMNAHPGDKDM4EL3MBTL1
SCHEMBL2823578 0.75 ALDH1A1 (0.33) ALDH1A1KDM4EL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C ALDH1A1 2123/4885LMNA 4322/4885HPGD 4517/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 ALDH1A1 3278/4885LMNA 3108/4885HPGD 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.